~~<i id='1B9C8426C6'><strike id='1B9C8426C6'><tt id='1B9C8426C6'><pre id='1B9C8426C6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：knowledge 2025-09-29 19:06:02 - browse：328

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Intellia plays down concerns on accidental germline transmission

focus

leisure time

focus

entertainment

explore

AdobeIonisPharmaceuticals,aCaliforniabiotechthathasspearheadedthedevelopmentofRNA-targetingmedicines

WSS

FDA seeks to regulate lab

FDA advisers vote against ALS treatment from BrainStorm

How the Dana

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Intellia plays down concerns on accidental germline transmission

Sudafed saga points to U.S. issues with evaluating older drugs

explore

focus

focus

Virginia high school admissions case could be legal follow

How the drug

Apple is now the first public company to be valued at $3 trillion

Listen: Who gets the credit for GLP

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Health officials lay out plans to cope with respiratory virus season

Walensky prepares to leave CDC — and Congress — behind

Senator probes 340B programs at Cleveland Clinic, Bon Secours

The cancer drug shortage isn’t new — and neither are the solutions

Health officials lay out plans to cope with respiratory virus season

leisure time

Biogen shutters digital health group, ends Apple study, in cost cutting move

Inequities make cancer less preventable for women: report

CDC says it’s too soon to assess risk posed by Covid subvariant

After a drawn out lobbying fight, ARPA

Biogen shutters digital health group, ends Apple study, in cost cutting move

Republicans love RFK Jr. What's that tell us about health in 2024?

focus

focus

entertainment

explore